Evidence map›Paper›PMID 42902376›Full record

ReviewBMC medical genomics2026

Identification of a putative founder variant in SLC30A10 associated with hypermanganesemia with dystonia 1 in Iranian patients: a case series and literature review.

Atieh Eslahi, Farzaneh Alizadeh, Arash Salmaninejad, Sadaf Ghanaatgar-Kasbi, Karim Naghipour Kojur, Mir Salar Kahaei, Leila Hamzehzadeh, Masoome Alerasool, Mahsa Sadat Asl Mohajeri, Azam Rastegar Moghaddam and 4 more

Abstract readReviewCase Reports
In one paragraph

Review in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Atieh Eslahi *Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Farzaneh Alizadeh *Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Arash SalmaninejadDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Sadaf Ghanaatgar-KasbiDepartment of Pharmacology-Physiology, Université de Sherbrooke - Campus de la santé, Sherbrooke, Québec, Canada.
Karim Naghipour KojurDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mir Salar KahaeiDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Leila HamzehzadehDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Masoome AlerasoolDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahsa Sadat Asl MohajeriDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Azam Rastegar MoghaddamDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Shima FarrokhiDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Yasamin YousefiDepartment of Biochemistry, Mashhad University of Ferdowsi, Mashhad, Iran.
Mehran Beiraghi ToosiRare Pediatric Neurological Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid MojarradDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. majidmojarrad11@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypermanganesemia with dystonia 1 (HMNDYT1) is an rare autosomal recessive condition resulting from pathogenic variants in the SLC30A10 gene. The presence of biallelic variants in this gene results in systemic accumulation of manganese, which leads to dystonia, polycythemia, and liver dysfunction. We conducted clinical and genetic evaluations of seven affected individuals from six Iranian consanguineous families, emphasizing the identification of potential founder mutations, and integrated this information with a total of 80 previously reported cases. Analysis of exome sequencing in all seven individuals affected revealed the presence of the identical homozygous variant in SLC30A10 (c.1006 C > T; p.His336Tyr), suggesting a potential founder effect. The estimated most recent common ancestor for these patients lived approximately 47 generations ago, suggesting an ancient mutation originating from a common ancestor. A literature review of 80 reported HMNDYT1 cases demonstrated that hypermanganesemia, T1 hyperintensity of the basal ganglia and dentate nuclei, dystonia, and polycythemia constitute the predominant clinical features. Symptom onset occurred primarily within the first five years of life (median: ~2 years, range: 0.25-57 years). Collectively, these observations underscore the need to identify potential founder variants and to more comprehensively characterize the genotypic and phenotypic spectrum of SLC30A10 to inform genetic counseling and population-based screening strategies.

Indexed as

Cation Transport ProteinsDystoniaFounder EffectMetal Metabolism, Inborn ErrorsAdolescentAdultChildChild, PreschoolFemaleHumansInfantIranMaleMetabolic DiseasesMiddle AgedMutationCation Transport ProteinsSLC30A10 protein, humanFounder variantHMNDYT1Hypermanganesemia with dystonia 1SLC30A10

Identifiers

PMID42902376
PMCPMC13685204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.